Pfizer Inc. [PFE] is -3.58% lower this YTD. Is it still time to buy?

Pfizer Inc. [NYSE: PFE] gained 0.76% on the last trading session, reaching $27.76 price per share at the time. The company report on February 19, 2024 at 7:45 AM that European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis.

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

If compared to the average trading volume of 46.71M shares, PFE reached a trading volume of 32964298 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Pfizer Inc. [PFE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $31.45 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 23, 2024. The new note on the price target was released on January 04, 2024, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another drop from $36 to $34, while UBS kept a Neutral rating on PFE stock. On October 16, 2023, analysts increased their price target for PFE shares from 38 to 39.

The Average True Range (ATR) for Pfizer Inc. is set at 0.58, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.68. The Price to Book ratio for the last quarter was 1.76, with the Price to Cash per share for the same quarter was set at 2.25. Price to Free Cash Flow for PFE in the course of the last twelve months was 32.70 with Quick ratio for the last quarter at 0.69.

Trading performance analysis for PFE stock

Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.91. With this latest performance, PFE shares dropped by -2.01% in over the last four-week period, additionally sinking by -24.28% over the last 6 months – not to mention a drop of -34.50% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 51.00, with the RSI for the last a single of trading hit 55.85, and the three-weeks RSI is set at 48.28 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 27.96, while it was recorded at 27.64 for the last single week of trading, and 32.89 for the last 200 days.

Pfizer Inc. [PFE]: A deeper dive into fundamental analysis

Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.69 and a Current Ratio set at 0.91.

Pfizer Inc. [PFE]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Pfizer Inc. posted 1.23/share EPS, while the average EPS was predicted by analysts to be reported at 0.98/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to -1.20%.

An analysis of Institutional ownership at Pfizer Inc. [PFE]

There are presently around $113.82 billion, or None% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in PFE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in PFE stock with ownership which is approximately 5.8325%.